Skip to content

Cannabis: all studies

Page 160 of 287: studies 1,591 to 1,600 of 2,864, newest first. Back to the cannabis overview

Research

Dorsolateral prefrontal cortex N-acetylaspartate/total creatine (NAA/tCr) loss in male recreational cannabis users.

Biological Psychiatry June 1, 2007 Derik Hermann, Alexander Sartorius, Helga Welzel et al.

Cannabinoids present neurotoxic and neuroprotective properties in in vitro studies, inconsistent alterations in human neuroimaging studies, neuropsychological deficits, and an increased risk for psychotic episodes. Proton magnetic resonance spectroscopy ((1)H-MRS), neuropsychological testing, and hair analysis for cannabinoids was performed in 13 male nontreatment-seeking recreational cannabis...

Revisión sobre el consumo de cannabis como factor de riesgo de la esquizofrenia

Adicciones June 1, 2007 F. Árias 13 citations

Cannabis use is extremely prevalent in young people and there is controversy over the psychosocial harm of this use. One risk stands out--that of the possibility of cannabis being a risk factor of an illness as serious and incapacitating as schizophrenia. An avalanche of information has emerged recently on this subject, which it is essential to review. There are a number of cohort studies that...

Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol.

Psychopharmacology June 2007 A A Boucher, Jonathon C Arnold, L Duffy et al.

Cannabis use may precipitate schizophrenia especially if the individual has a genetic vulnerability to this mental disorder. Human and animal research indicates that neuregulin 1 (Nrg1) is a susceptibility gene for schizophrenia. The aim of this study was to investigate whether dysfunction in the Nrg1 gene modulates the behavioural effects of Delta(9)-tetrahydrocannabinol (THC), the major...

Nicotinic facilitation of delta9-tetrahydrocannabinol discrimination involves endogenous anandamide.

Journal of Pharmacology and Experimental Therapeutics June 2007 Marcello Solinas, Maria Scherma, Gianluigi Tanda et al.

Systemic administration of the main active ingredient in cannabis, Delta9-tetrahydrocannabinol (THC), alters extracellular levels of acetylcholine in several brain areas, suggesting an involvement of the cholinergic system in the psychotropic effects of cannabis. Here, we investigated whether drugs acting at either nicotinic or muscarinic receptors can modulate the discriminative effects of...

Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers.

Neuropsychopharmacology June 2007 Margaret Haney

In non-human animals, opioid antagonists block the reinforcing and discriminative-stimulus effects of Delta(9)-tetrahydrocannabinol (THC), while in human marijuana smokers, naltrexone (50 mg) enhances the reinforcing and subjective effects of THC. The objective of this study was to test a lower, more opioid-selective dose of naltrexone (12 mg) in combination with THC. The influence of...

Cannabis and psychosis: what is the link?

Journal of Psychoactive Drugs June 1, 2007 Mohamed Ben Amar, Stéphane Potvin

Growing evidence supports the hypothesis that cannabis consumption is a risk factor for the development of psychotic symptoms. Nonetheless, controversy remains about the causal nature of the association. This review takes the debate further through a critical appraisal of the evidence. An electronic search was performed, allowing to identify 622 studies published until June 1st 2005....

Combined immunomodulating properties of 3,4‐methylenedioxymethamphetamine (MDMA) and cannabis in humans

Addiction May 22, 2007 Roberta Pacifici, Piergiorgio Zuccaro, Magı́ Farré et al. 39 citations

ABSTRACT Aims Cell‐mediated immune function and the occurrence of mild infectious diseases was investigated. Participants Polydrug consumers of 3,4‐methylenedioxymethamphetamine (MDMA) and cannabis ( n = 37) compared to cannabis users only ( n = 23) and control group ( n = 34). Design A longitudinal prospective study with three cross‐sectional evaluations at time 0 and at 6 months and 1 year...

Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats.

Psychopharmacology May 2007 Nicole L Schramm-Sapyta, Young May Cha, Saba Chaudhry et al.

Unpleasant side effects of drugs of abuse often limit their repeated use; however, such effects may be attenuated in adolescents compared to adults. We investigated whether the anxiogenic, aversive, or locomotor effects of delta-9-tetrahydrocannabinol (THC) differ between adolescent and adult rats. We used the elevated plus maze (EPM) and light-dark tests of anxiety, the conditioned taste...

The relationship between non‐acute adolescent cannabis use and cognition

Drug and Alcohol Review May 1, 2007 Megan A. Harvey, John D. Sellman, Richard Porter et al.

AbstractResearch indicates that cannabis continues to be a popular illegal drug internationally. Furthermore, adolescent rates of use appear to be significant. Whilst the non‐acute effect of cannabis use on adult cognition has been extensively researched, there has been less examination of adolescents. This study aimed to investigate the non‐acute relationship between cannabis and cognitive...

Effects of smoking marijuana on focal attention and brain blood flow.

Human psychopharmacology April 2007 Daniel S O'Leary, Robert I Block, Julie A Koeppel et al.

Using an attention task to control cognitive state, we previously found that smoking marijuana changes regional cerebral blood flow (rCBF). The present study measured rCBF during tasks requiring attention to left and right ears in different conditions. Twelve occasional marijuana users (mean age 23.5 years) were imaged with PET using [15O]water after smoking marijuana or placebo cigarettes as...